Mirtin (Mirtazapine)

Mirtazapine, the active ingredient in Mirtin, is a Noradrenergic and specific serotonergic antidepressant (NaSSA) presented as an oral dosage form for oral use. It is prescribed for the treatment of major depressive disorder in adult patients.

GNH USA supplies Mirtin as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Mirtin (mirtazapine) is indicated for depressive disorders and works by modulating noradrenergic and serotonergic pathways.

- Major depressive disorder: alleviates depressive symptoms and improves mood in adult patients. - Depressive episodes associated with major depressive disorder: reduces severity and duration of episodes. - Adjunctive therapy for anxiety symptoms in depression: may improve sleep and reduce anxiety.

Mirtin may cause a range of adverse reactions, which are generally classified by frequency and severity.

Common Side Effects: - Sedation or drowsiness - Increased appetite and weight gain - Dry mouth - Constipation

Serious or Rare Side Effects: - Agranulocytosis or severe neutropenia - Suicidal thoughts or behavior - Serotonin syndrome when combined with other serotonergic agents

When prescribing Mirtin, clinicians should consider several precautionary measures to ensure safe use. - Assess for suicidal ideation: monitor patients closely during initiation and dose changes. - Monitor weight and appetite: significant weight gain may occur. - Use caution in hepatic impairment: dose adjustment may be required. - Avoid abrupt discontinuation: taper to reduce withdrawal symptoms. - Consider dose reduction in elderly: increased sensitivity to sedative effects. - Store at room temperature: keep in the original container, protect from moisture.

Mirtin can interact with other medicines, altering its effectiveness or increasing risk of adverse effects.

Major Interactions (Avoid): - Concurrent MAO inhibitors: risk of hypertensive crisis; a 14‑day washout is required. - Other central nervous system depressants (e.g., benzodiazepines, alcohol): may enhance sedation and respiratory depression.

Moderate Interactions (Monitor Closely): - Selective serotonin reuptake inhibitors or SNRIs: increased risk of serotonin syndrome. - CYP3A4 inhibitors (e.g., ketoconazole, erythromycin): may raise mirtazapine plasma levels. - CYP3A4 inducers (e.g., carbamazepine, phenytoin): may reduce therapeutic effect.